Objective: To examine the effects of aducanumab treatment on brain amyloid beta (Aβ) plaque levels in prespecified baseline and disease characteristics subgroups of patients from the Phase 3 EMERGE and ENGAGE trials.Background: Aducanumab is a human monoclonal antibody that selectively targets ...
EMERGE (NCT02484547) and ENGAGE (NCT02477800) were global Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials that evaluated the efficacy and safety of aducanumab in patients with early AD with confirmed amyloid pathology (18, 19, 20). Final analyses...
EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer's Disease Samantha Budd Haeberlein,1 Christian von Hehn,1 Ying Tian,1 Spyros Chalkias,1 Kumar Kandadi Muralidharan,1 Tianle Chen,1 Shuang Wu,1 Jie Li,1 LeAnne Skordos,1 Laura ...
The decision to engage in a costly search is driven by the possibility that richer resources will be found in other parts of the environment and is thought to depend on incentive signals carried by DA and other neuromodulators (Berridge and Robinson, 1998; Cohen et al, 2007; Adams et al,...
The decision to engage in a costly search is driven by the possibility that richer resources will be found in other parts of the environment and is thought to depend on incentive signals carried by DA and other neuromodulators (Berridge and Robinson, 1998; Cohen et al, 2007; Adams et al,...
We recorded SEEG activity during rest and a pure-tone stimulation task. The resting condition consisted in three intervals of three minutes each, with the patients sitting awake with eyes closed. The auditory stimuli were composed of 100 pure tone trials, 30 ms long, presented binaurally at ...
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed ...
(the marketed dose) over 24 months in participants with Alzheimer's disease who were enrolled in aducanumab clinical trials (PRIME/EVOLVE/EMERGE/ENGAGE) when the studies were discontinued (March 21, 2019).Results: A total of 902 participants from EMERGE, 868 from ENGAGE, and 29 from PRIME ...
A positive treatment effect of aducanumab on efficacy endpoints was observed in EMERGE, but not in ENGAGE.doi:10.14283/jpad.2024.106Yasuo TodaBiogen Japan Ltd. 1-4-1 Nihonbashi, Chuo-ku 103-0027 Tokyo JapanT. Iwatsubogrid.412708.80000 0004 1764 7572Unit for Early and Exploratory Clinical ...
Most letters encouraged participants to engage in proactive actions. The most common affective stance encouraged participants to believe they can improve their health or effectively manage any health condition indicated by the genetic test, and it was found in 27 of 43 (63%) letters across eight ...